Literature DB >> 33471201

Tissue Engineering for Musculoskeletal Regeneration and Disease Modeling.

Zhong Li1, Shiqi Xiang1, Eileen N Li1,2, Madalyn R Fritch1, Peter G Alexander1, Hang Lin1,2, Rocky S Tuan3,4,5.   

Abstract

Musculoskeletal injuries and associated conditions are the leading cause of physical disability worldwide. The concept of tissue engineering has opened up novel approaches to repair musculoskeletal defects in a fast and/or efficient manner. Biomaterials, cells, and signaling molecules constitute the tissue engineering triad. In the past 40 years, significant progress has been made in developing and optimizing all three components, but only a very limited number of technologies have been successfully translated into clinical applications. A major limiting factor of this barrier to translation is the insufficiency of two-dimensional cell cultures and traditional animal models in informing the safety and efficacy of in-human applications. In recent years, microphysiological systems, often referred to as organ or tissue chips, generated according to tissue engineering principles, have been proposed as the next-generation drug testing models. This chapter aims to first review the current tissue engineering-based approaches that are being applied to fabricate and develop the individual critical elements involved in musculoskeletal organ/tissue chips. We next highlight the general strategy of generating musculoskeletal tissue chips and their potential in future regenerative medicine research. Exemplary microphysiological systems mimicking musculoskeletal tissues are described. With sufficient physiological accuracy and relevance, the human cell-derived, three-dimensional, multi-tissue systems have been used to model a number of orthopedic disorders and to test new treatments. We anticipate that the novel emerging tissue chip technology will continually reshape and improve our understanding of human musculoskeletal pathophysiology, ultimately accelerating the development of advanced pharmaceutics and regenerative therapies.

Entities:  

Keywords:  Biological induction; Biomaterial; Disease modeling; Drug testing; Growth factors; Microphysiological system; Organoid; Regenerative medicine; Stem cells; Tissue chip

Mesh:

Year:  2021        PMID: 33471201      PMCID: PMC8049527          DOI: 10.1007/164_2020_377

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  158 in total

1.  Insulin-like growth factor in muscle growth and its potential abuse by athletes.

Authors:  G R Adams
Journal:  Br J Sports Med       Date:  2000-12       Impact factor: 13.800

Review 2.  Exploiting extracellular matrix-stem cell interactions: a review of natural materials for therapeutic muscle regeneration.

Authors:  Drew Kuraitis; Céline Giordano; Marc Ruel; Antonio Musarò; Erik J Suuronen
Journal:  Biomaterials       Date:  2011-10-19       Impact factor: 12.479

3.  Cell-secreted extracellular matrix, independent of cell source, promotes the osteogenic differentiation of human stromal vascular fraction.

Authors:  Jenna N Harvestine; Hakan Orbay; Jonathan Y Chen; David E Sahar; J Kent Leach
Journal:  J Mater Chem B       Date:  2018-05-29       Impact factor: 6.331

4.  The growth, development and phosphatase activity of embryonic avian femora and limb-buds cultivated in vitro.

Authors:  H B Fell; R Robison
Journal:  Biochem J       Date:  1929       Impact factor: 3.857

5.  Electrospun silk-BMP-2 scaffolds for bone tissue engineering.

Authors:  Chunmei Li; Charu Vepari; Hyoung-Joon Jin; Hyeon Joo Kim; David L Kaplan
Journal:  Biomaterials       Date:  2006-02-03       Impact factor: 12.479

6.  Exploring the in vitro and in vivo compatibility of PLA, PLA/GNP and PLA/CNT-COOH biodegradable nanocomposites: Prospects for tendon and ligament applications.

Authors:  Viviana Correia Pinto; Raquel Costa-Almeida; Ilda Rodrigues; Luísa Guardão; Raquel Soares; Rui Miranda Guedes
Journal:  J Biomed Mater Res A       Date:  2017-05-04       Impact factor: 4.396

7.  Tendon-Derived Extracellular Matrix Enhances Transforming Growth Factor-β3-Induced Tenogenic Differentiation of Human Adipose-Derived Stem Cells.

Authors:  Guang Yang; Benjamin B Rothrauff; Hang Lin; Shuting Yu; Rocky S Tuan
Journal:  Tissue Eng Part A       Date:  2017-01-10       Impact factor: 3.845

8.  Functional comparison of human-induced pluripotent stem cell-derived mesenchymal cells and bone marrow-derived mesenchymal stromal cells from the same donor.

Authors:  Solvig Diederichs; Rocky S Tuan
Journal:  Stem Cells Dev       Date:  2014-04-28       Impact factor: 3.272

9.  Three-dimensional culture and transforming growth factor beta3 synergistically promote tenogenic differentiation of equine embryo-derived stem cells.

Authors:  Tom Barsby; Emma P Bavin; Debbie J Guest
Journal:  Tissue Eng Part A       Date:  2014-04-21       Impact factor: 3.845

10.  Prospective isolation of chondroprogenitors from human iPSCs based on cell surface markers identified using a CRISPR-Cas9-generated reporter.

Authors:  Amanda Dicks; Chia-Lung Wu; Nancy Steward; Shaunak S Adkar; Charles A Gersbach; Farshid Guilak
Journal:  Stem Cell Res Ther       Date:  2020-02-18       Impact factor: 8.079

View more
  3 in total

1.  Cell Therapy in Veterinary Medicine as a Proof-of-Concept for Human Therapies: Perspectives From the North American Veterinary Regenerative Medicine Association.

Authors:  Boaz Arzi; Tracy L Webb; Thomas G Koch; Susan W Volk; Dean H Betts; Ashlee Watts; Laurie Goodrich; Michael S Kallos; Amir Kol
Journal:  Front Vet Sci       Date:  2021-11-30

Review 2.  Human Organ-on-a-Chip Microphysiological Systems to Model Musculoskeletal Pathologies and Accelerate Therapeutic Discovery.

Authors:  Raquel E Ajalik; Rahul G Alenchery; John S Cognetti; Victor Z Zhang; James L McGrath; Benjamin L Miller; Hani A Awad
Journal:  Front Bioeng Biotechnol       Date:  2022-03-14

Review 3.  Genetics of osteoarthritis.

Authors:  G Aubourg; S J Rice; P Bruce-Wootton; J Loughlin
Journal:  Osteoarthritis Cartilage       Date:  2021-03-17       Impact factor: 7.507

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.